Esperion Therapeutics, Inc.

Warner-lambert Company

Other

Ribozyme Pharmaceuticals, Incorporated

Warner Lambert LLC

Roger Schofield Newton

Charles Larry Bisgaier

Diane Elaine MacDougall

Noah Laban Rosenberg

James A McSwiggen

Dan T Stinchcomb

Jean-Louis Henri Dasseux

Randy Ranjee Ramharack

Michael Edward Pape

Thomas J Rea

Timothy R Hurley

Judith S Leopold

Stephen L Pinkosky

Michael Aviram

Sergey V Filippov

Mira Rosenblat

Rai Ajit K Srivastava

Diane Elaine Macdougall

Disclosed herein are compositions comprising fixed doses of ETC-1002 and Ezetimibe. Also disclosed herein are methods for using fixed doses of ETC-1002 and Ezetimibe. Uses include methods of treating cardiovascular disease or reducing the risk of cardiovascular disease in a subject. Uses also include methods of treating hypercholesterolemia in a subject.

Fixed dose combinations and formulations comprising ETC1002 and ezetimibe and methods of treating or reducing the risk of cardiovascular disease

Disclosed herein are compositions comprising fixed doses of ETC-1002 and one or more statins. Also disclosed herein are methods for using fixed doses of ETC-1002 and one or more statins. Uses include methods of treating cardiovascular disease or reducing the risk of cardiovascular disease in a subject. Uses also include methods of treating hypercholesterolemia in a subject.

Fixed dose combinations and formulations comprising ETC1002 and one or more statins and methods of treating or reducing cardiovascular disease

The present invention provides a pharmaceutical composition comprising a mixture of apolipoproteins. Methods for elevating HDL levels are also provided as are methods for the treatment and prevention of cardiovascular diseases and disorders, inflammation and metabolic diseases.

Apolipoprotein mixtures

The invention is a pharmaceutical composition comprising a carboxyalkylether which lowers triglycerides and elevated HDL, and a statin which inhibits HMG-CoA reductase, thereby reducing LDL, said composition being useful for treating vascular diseases.

Statin-carboxyalkylether combinations

The present invention relates to methods for high information content (HIC) analysis or screening of complex biological systems using Fourier transform mass spectrometry (FTMS). The present methods are useful for analyzing complex biological mixtures containing both high molecular weight molecules (e.g., polynucleotides, proteins, polysaccharides) and low molecular weight molecules (e.g., oligonucleotides, peptides, lipids, oligosaccharides, steroid hormones, catabolic and metabolic intermediates) permit the elucidation of molecular differences between complex biological samples, and permit the identification of biologically active molecules (e.g. therapeutically active drugs, etc.).

Fourier transform mass spectrometry of complex biological samples

Novel combinations of inhibitors of protein farnesyltransferase enzymes and HMG CoA reductases enzymes are described, as well as methods for the preparation and pharmaceutical compositions of the same, which are useful in preventing or treating cancer, restenosis, psoriasis, endometriosis, atherosclerosis, or viral infections.

Combinations of protein farnesyltransferase and HMG CoA reductase inhibitors and their use to treat cancer

Hydroxylated derivatives of cholesterol lowering agents inhibit the oxidation of lipoproteins, and are thus useful for preventing the progression of atherogenesis and resultant vascular diseases, including heart attacks.

Inhibition of lipoprotein oxidation

Enzymatic RNA molecules which cleave apo(a) mRNA.

Ribozymes targeted to APO(a) RNA

Ribozymes targeted to apo(a) mRNA

Growing community of inventors

Ann Arbor, MI, United States of America

Roger Schofield Newton